Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering

Rhea-AI Summary

Devonian Health Group (TSXV:GSD, OTCQB:DVHGF) announced a proposed underwritten public offering of common shares (and/or pre-funded warrants) and warrants, together with an expected listing of its common shares and warrants on the NYSE American under the symbols DHGR and DHGRW, respectively. The listing remains subject to final authorization of the company's application and ongoing compliance with exchange rules, and the Offering is subject to market conditions and regulatory approval, with size and pricing yet to be determined.

According to Devonian, its shares are expected to continue trading on the OTCQB until pricing of the Offering, after which OTCQB trading will terminate once the NYSE American listing is effective. The company has also reserved the symbol DHGR on the TSX Venture Exchange and intends to change its current symbol from GSD to DHGR at a later date. ThinkEquity is acting as sole book-running manager, and a registration statement has been filed with the SEC but is not yet effective; no securities will be offered or sold to investors resident in Québec or elsewhere in Canada in connection with this Offering.

Positive

• Planned NYSE American listing for common shares (DHGR) and warrants (DHGRW)
• Underwritten public offering structure with ThinkEquity as sole book-running manager
• TSXV ticker alignment planned from GSD to reserved symbol DHGR

Negative

• Offering and NYSE American listing both subject to market and regulatory conditions
• No Canadian investors will be offered or sold securities in this Offering
• Registration statement not yet effective, so timing and terms remain uncertain

Market Context

The platform categorized current short positioning as low, providing limited short-interest context ...

Analysis

The platform categorized current short positioning as low, providing limited short-interest context for the proposed offering. Investors still lacked disclosed offering size, terms, and an effective registration statement.

Key Figures

Announcement date: July 27, 2026

1 metrics

Announcement date July 27, 2026 Offering and proposed NYSE American listing announcement

Historical Context

5 past events · Latest: Mar 30 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 30	shareholder meeting	Neutral	-34.3%	Shareholders elected directors and approved a larger stock option pool.
Mar 25	earnings report	Negative	-34.3%	Quarterly losses widened while cash declined to $1.3M.
Feb 19	preclinical data	Positive	+149.7%	Liver-on-a-chip data showed dose-dependent anti-fibrotic and anti-inflammatory activity.
Feb 17	patent strategy	Positive	+149.7%	Patent applications described chemical fingerprint and manufacturing controls.
Feb 12	preclinical data	Positive	+149.7%	MASH study reported dose-dependent gene effects across fibrosis pathways.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive preclinical and patent announcements aligned with gains, while the shareholder-meeting announcement diverged from its negative price reaction.

Key Terms

underwritten public offering, pre-funded warrants, registration statement, book-running manager

4 terms

underwritten public offering financial

"it is conducting an underwritten public offering of its common shares"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

pre-funded warrants financial

"pre-funded warrants in lieu thereof"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

registration statement regulatory

"A registration statement relating to the proposed Offering has been filed"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

book-running manager financial

"ThinkEquity is acting as the sole book-running manager"

A book-running manager is the lead organizer responsible for coordinating a large financial sale, such as issuing new stocks or bonds. They oversee preparing all necessary documents, setting the sale’s price, and finding buyers, much like a concert promoter arranging a major event. Their role matters to investors because they help ensure the offering is successfully sold at the best possible terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

QUÉBEC, July 27, 2026 /PRNewswire/ -- Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today announces that it is conducting an underwritten public offering of its common shares (and/or pre-funded warrants in lieu thereof) and warrants (the "Warrants") (the "Offering"). Concurrently with the Offering, the Company expects its common shares and Warrants to be approved for listing on the NYSE American LLC (the "NYSE American") under the symbols "DHGR" and "DHGRW", respectively, subject to final authorization of the Company's listing application and continued compliance with the exchange rules. Additional details regarding the Offering will be provided through the Company's filings with the Securities and Exchange Commission (the "SEC") and those made in other filings with the applicable securities regulators of Canada. The Offering is subject to market conditions and regulatory approval, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.

The Company expects that its common shares will continue to be quoted on the OTCQB Venture Market until the pricing of the Offering. Upon listing on the NYSE American, trading of the common shares on the OTCQB will terminate. Shareholders of the Company do not need to take any action prior to the listing of shares on the NYSE American. The Company has also reserved the symbol "DHGR" on the TSX Venture Exchange (the "TSXV") and intends to request that its current trading symbol be changed at a later date from "GSD" to "DHGR".

ThinkEquity is acting as the sole book-running manager for the Offering.

A registration statement relating to the proposed Offering has been filed with the SEC but has not yet been declared effective. Securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement is declared effective by the SEC.

The proposed Offering will be made only by means of a prospectus. Copies of the preliminary prospectus contained in the registration statement may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004.

This communication does not constitute an offer, or a solicitation of an offer, to buy or sell any securities, investment or other specific product, or a solicitation of any vote or approval, nor shall there be any sale of securities, investment or other specific product in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No securities will be offered or sold to any investor resident in Québec or elsewhere in Canada in connection with the Offering.

About Devonian

Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune fibroinflammatory disease with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription drugs for the treatment of fibroinflammatory autoimmune diseases including but not limited to atopic dermatitis, radiodermatitis and ulcerative colitis.

Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Quebec, Canada where it owns a state-of-the-art extraction facility. Devonian is traded publicly on the TSXV (TSXV: GSD) and currently quoted on the OTCQB Venture Market (OTCQB: DVHGF).

Cautionary Note Regarding Forward-Looking Statements

All statements, other than statements of historical fact contained in this press release, including but not limited to those relating to the anticipated listing on the NYSE American and concurrent underwritten public offering and the proposed NYSE American and proposed change to the TSXV ticker symbols, and, generally, the statements contained under the "About Devonian" section, constitute "forward-looking information" or "forward-looking statements" within the meaning of applicable securities laws (collectively, "forward-looking statements"). These forward-looking statements are based on the Company's current expectations, estimates and assumptions as of the date of this press release. Such forward-looking statements may be identified by the use of words such as "anticipates," "believes," "expects," "intends," "plans," "may," "could," "would," "should," "will," or similar expressions, including negative or grammatical variations thereof, indicating that certain actions, events or results may, could or will occur or be achieved.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in the Company's other filings with the applicable securities regulators of Canada and in the "Risk Factors" section in the prospectus related to the Offering filed with the SEC. The Company disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/devonian-health-group-announces-proposed-listing-on-the-nyse-american-with-concurrent-underwritten-public-offering-302835763.html

SOURCE Devonian Health Group Inc.

FAQ

What did Devonian Health Group (TSXV:GSD, OTCQB:DVHGF) announce on July 27, 2026 about DHGR?

Devonian Health Group announced a proposed underwritten public offering and an expected NYSE American listing under symbol DHGR. According to Devonian, the listing and Offering remain subject to market conditions, regulatory approvals, and final authorization of its NYSE American listing application.

What are the new NYSE American ticker symbols DHGR and DHGRW for Devonian Health Group?

Devonian Health Group expects its common shares to trade on NYSE American as DHGR and its warrants as DHGRW. According to Devonian, these listings are conditional on final NYSE American authorization and continued compliance with the exchange’s rules.

How will the NYSE American listing affect Devonian Health Group’s OTCQB (DVHGF) quotation?

Devonian expects its common shares to continue on the OTCQB until the Offering is priced. According to Devonian, once the NYSE American listing becomes effective, trading of its common shares on the OTCQB Venture Market will terminate.

Will Devonian Health Group shares keep trading on the TSX Venture Exchange after the DHGR listing?

Devonian indicates its shares remain on the TSXV, where it has reserved the DHGR symbol. According to Devonian, it intends to request a change of its TSXV trading symbol from GSD to DHGR at a later date.

Who is managing the Devonian Health Group DHGR underwritten public offering?

ThinkEquity is acting as the sole book-running manager for the proposed Devonian offering. According to Devonian, the Offering will proceed only after SEC effectiveness of the registration statement and will be made solely by means of a prospectus.

Can Canadian or Quebec investors participate in the Devonian Health Group DHGR public offering?

No, the Devonian offering will not include investors resident in Québec or elsewhere in Canada. According to Devonian, no securities will be offered or sold to any investor resident in Canada in connection with this Offering.

Has the SEC declared Devonian Health Group’s DHGR offering registration statement effective?

No, Devonian reports that its registration statement has been filed with the SEC but is not yet effective. According to Devonian, securities cannot be sold or offers accepted until the SEC declares that registration statement effective.